Breast Cancer
Feature
Tucatinib-Trastuzumab Benefit ‘Remarkable’ in HER2-positive mCRC
Oncologists emphasize that the tucatinib-trastuzumab combination represents a major breakthrough.
Conference Coverage
Survey Spotlights Identification of Dermatologic Adverse Events From Cancer Therapies
Survey respondents classify and grade morbilliform, psoriasiform, and papulopustular rashes based on a review of photographs and text descriptions...
Conference Coverage
New mRNA Vaccines in Development for Cancer and Infections
Different forms and designations of mRNA vaccines are used, depending on the application and desired effect.
From the Journals
Can a Risk Score Predict Kidney Injury After Cisplatin?
Researchers have developed a risk algorithm to predict acute kidney injury after cisplatin administration and tested it using data from six US...
From the Journals
Do Patients Benefit from Cancer Trial Participation?
Researchers conduct a meta-analysis comprising 141 comparisons of an investigational drug and a control treatment, which include immunotherapies...
Feature
Do Health-Related Social Needs Raise Mortality Risk in Cancer Survivors?
Researchers examine links between mortality risk and health-related social needs in patients who had cancer.
From the Journals
Terminal Cancer: What Matters to Patients and Caregivers
Patients and caregivers are less aligned on decisions about cost containment than end-of-life goals.
Feature
The Long, Controversial Search for a ‘Cancer Microbiome’
Research raised as many questions as answers about what we do and don’t know about microbiota and cancer.
From the Journals
Potential Cure for Early BRCA-Mutated Breast Cancer?
All patients who recieved a combination of standard chemotherapy with olaparib were alive at 36 months.
Feature
Routine Breast Cancer Screening Should Start at Age 40: USPSTF
Three JAMA editorials address concerns about the new recommendations.
From the Journals
Could Aspirin Help Treat Breast Cancer?
Researchers conduct first randomized, placebo-controlled trial of aspirin in survivors of breast cancer.